Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 7/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 7/20 | 0.37 |
| ▸ | MMP13 | P45452 | 5/20 | 0.37 |
| ▸ | MMP14 | P50281 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20200600 | 1.00 | APLNR (0.41) | APLNRADAMTS4MMP13MMP14KCNH2 | |
| SCHEMBL20188961 | 1.00 | APLNR (0.41) | APLNRADAMTS4MMP13MMP14KCNH2 | |
| SCHEMBL20188351 | 0.84 | APLNR (0.40) | APLNRADAMTS4MMP13MMP14KCNH2 | |
| SCHEMBL20190107 | 0.84 | APLNR (0.40) | APLNRADAMTS4MMP13MMP14KCNH2 | |
| SCHEMBL20188375 | 0.84 | APLNR (0.40) | APLNRADAMTS4MMP13MMP14KCNH2 | |
| SCHEMBL12463409 | 0.74 | JAK2 (0.33) | APLNRADAMTS4MMP13MMP14KCNH2 | |
| SCHEMBL18428183 | 0.74 | JAK2 (0.33) | APLNRADAMTS4MMP13MMP14KCNH2 | |
| SCHEMBL18246875 | 0.72 | APLNR (0.49) | APLNR | |
| SCHEMBL21859524 | 0.72 | JAK2 (0.37) | APLNRJAK2JAK3 | |
| SCHEMBL18245829 | 0.72 | APLNR (0.49) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3541792-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018097944-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, APLNR | APLNR 3/4885ADAMTS4 3849/4885MMP13 4151/4885 |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | TBXA2R, AGTR1, APLNR | APLNR 3/4885ADAMTS4 3849/4885MMP13 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.